Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The targeted therapy delayed disease progression or death by approximately nine months.
Adding the CDK 4/6 inhibitor to hormone prolonged survival by a year.
Exkivity is approved for adults with advanced non-small-cell lung cancer with specific EGFR mutations.
The IDH1 inhibitor is the third medication approved this year for hard-to-treat bile duct cancer.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Targeted therapy and immunotherapy combination doubles response rate for people with advanced renal cell carcinoma.
A family physician diagnosed with chronic lymphocytic leukemia, Brian Koffman cofounded the CLL Society. He lives in Claremont, California.
A combination of two targeted therapies led to long-lasting remission in a small study of patients with hairy cell leukemia.
Several new medications for kidney cancer have been approved in recent years.
Sonia Dolinger runs a meal delivery business and fundraises for cancer research. She has chronic lymphocytic leukemia.
PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
New targeted therapy shrank tumors in nearly a quarter of patients with bile duct cancer.
Rybrevant is the first treatment for people with advanced non-small-cell lung cancer whose tumors have EGFR exon 20 insertion mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.